Journal
PROGRESS IN NEUROBIOLOGY
Volume 95, Issue 2, Pages 163-212Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pneurobio.2011.08.004
Keywords
Parkinson's disease; Serotonin; 5-HT1A; 5-HT1B/1D; 5-HT2A; 5-HT2C; 5-HT3; 5-HT4; 5-HIAA; MPTP; 6-OHDA; Dyskinesia; L-DOPA
Categories
Funding
- Cure Parkinson's Trust
- Krembil Neuroscience Fund
- Edmond J Safra Philanthropic Foundation
- Parkinson Society Canada
- Canadian Institutes of Health Research
- Atuka
- Merck
- Merck Serono
- Teva
- Atuka Ltd.
Ask authors/readers for more resources
Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline in dopamine levels in the striatum, a breadth of non-motor features and treatment-related complications in which the serotonergic system plays a pivotal role are increasingly recognised. Serotonin (5-HT)-mediated neurotransmission is altered in PD and the roles of the different 5-HT receptor subtypes in disease manifestations have been investigated. The aims of this article are to summarise and discuss all published preclinical and clinical studies that have investigated the serotonergic system in PD and related animal models, in order to recapitulate the state of the current knowledge and to identify areas that need further research and understanding. (C) 2011 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available